Cargando…

A Proposed Methodology for a Risk Assessment-Based Liposome Development Process

The requirements of a liposomal formulation vary depending on the pharmaceutical indication, the target patient population, and the corresponding route of administration. Different preparation methods require various material attributes (MAs) (properties and characteristics of the components) and pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Németh, Zsófia, Pallagi, Edina, Dobó, Dorina Gabriella, Csóka, Ildikó
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760874/
https://www.ncbi.nlm.nih.gov/pubmed/33260443
http://dx.doi.org/10.3390/pharmaceutics12121164
_version_ 1783627436004474880
author Németh, Zsófia
Pallagi, Edina
Dobó, Dorina Gabriella
Csóka, Ildikó
author_facet Németh, Zsófia
Pallagi, Edina
Dobó, Dorina Gabriella
Csóka, Ildikó
author_sort Németh, Zsófia
collection PubMed
description The requirements of a liposomal formulation vary depending on the pharmaceutical indication, the target patient population, and the corresponding route of administration. Different preparation methods require various material attributes (MAs) (properties and characteristics of the components) and process parameters (PPs) (settings of the preparation method). The identification of the quality target product profile for a liposome-based formulation, the critical quality attributes of the liposomes, and the possible MAs and PPs that may influence the key characteristics of the vesicles facilitates pharmaceutical research. Researchers can systematise their knowledge by using the quality by design (QbD) approach. The potential factors that influence the quality of the product can be collected and studied through a risk assessment process. In this paper, the requirements of a liposome formulation prepared via the thin-film hydration preparation technique are presented; furthermore, the possible factors that have an impact on the quality of the final product and have to be considered and specified during the development of a liposomal formulation are herein identified and collected. The understanding and the application of these elements of QbD in the pharmaceutical developments help to influence the quality, the achievements, and the success of the formulated product.
format Online
Article
Text
id pubmed-7760874
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-77608742020-12-26 A Proposed Methodology for a Risk Assessment-Based Liposome Development Process Németh, Zsófia Pallagi, Edina Dobó, Dorina Gabriella Csóka, Ildikó Pharmaceutics Article The requirements of a liposomal formulation vary depending on the pharmaceutical indication, the target patient population, and the corresponding route of administration. Different preparation methods require various material attributes (MAs) (properties and characteristics of the components) and process parameters (PPs) (settings of the preparation method). The identification of the quality target product profile for a liposome-based formulation, the critical quality attributes of the liposomes, and the possible MAs and PPs that may influence the key characteristics of the vesicles facilitates pharmaceutical research. Researchers can systematise their knowledge by using the quality by design (QbD) approach. The potential factors that influence the quality of the product can be collected and studied through a risk assessment process. In this paper, the requirements of a liposome formulation prepared via the thin-film hydration preparation technique are presented; furthermore, the possible factors that have an impact on the quality of the final product and have to be considered and specified during the development of a liposomal formulation are herein identified and collected. The understanding and the application of these elements of QbD in the pharmaceutical developments help to influence the quality, the achievements, and the success of the formulated product. MDPI 2020-11-29 /pmc/articles/PMC7760874/ /pubmed/33260443 http://dx.doi.org/10.3390/pharmaceutics12121164 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Németh, Zsófia
Pallagi, Edina
Dobó, Dorina Gabriella
Csóka, Ildikó
A Proposed Methodology for a Risk Assessment-Based Liposome Development Process
title A Proposed Methodology for a Risk Assessment-Based Liposome Development Process
title_full A Proposed Methodology for a Risk Assessment-Based Liposome Development Process
title_fullStr A Proposed Methodology for a Risk Assessment-Based Liposome Development Process
title_full_unstemmed A Proposed Methodology for a Risk Assessment-Based Liposome Development Process
title_short A Proposed Methodology for a Risk Assessment-Based Liposome Development Process
title_sort proposed methodology for a risk assessment-based liposome development process
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7760874/
https://www.ncbi.nlm.nih.gov/pubmed/33260443
http://dx.doi.org/10.3390/pharmaceutics12121164
work_keys_str_mv AT nemethzsofia aproposedmethodologyforariskassessmentbasedliposomedevelopmentprocess
AT pallagiedina aproposedmethodologyforariskassessmentbasedliposomedevelopmentprocess
AT dobodorinagabriella aproposedmethodologyforariskassessmentbasedliposomedevelopmentprocess
AT csokaildiko aproposedmethodologyforariskassessmentbasedliposomedevelopmentprocess
AT nemethzsofia proposedmethodologyforariskassessmentbasedliposomedevelopmentprocess
AT pallagiedina proposedmethodologyforariskassessmentbasedliposomedevelopmentprocess
AT dobodorinagabriella proposedmethodologyforariskassessmentbasedliposomedevelopmentprocess
AT csokaildiko proposedmethodologyforariskassessmentbasedliposomedevelopmentprocess